Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-RUNX3 antisense oligonucleotide
- Development stage
- Preclinical
- Lead developer
- Boston Children's Hospital
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraarticular
01
Overview
Anti-RUNX3 antisense oligonucleotide is an oligonucleotide-based therapeutic designed to target and inhibit the expression of Runt-related transcription factor 3 (RUNX3). RUNX3 is a key transcription factor involved in the convergent differentiation pathway of synovial CD8+ tissue-resident memory T cells (TRM) from circulating effector memory (TEM) and central memory (TCM) T cells in the arthritic synovium. By blocking RUNX3 expression, the antisense oligonucleotide inhibits TRM formation and differentiation, thereby reducing joint-specific memory and preventing arthritis flares. Developed by researchers at Boston Children's Hospital, anti-RUNX3 antisense oligonucleotide is being investigated in preclinical models of rheumatoid arthritis and chronic arthritis.
- Other names
- RUNX3 antisense oligonucleotideRUNX-3 antisense oligonucleotideRUNX 3 antisense oligonucleotideRunx3 ASORunx-3 ASORunx 3 ASOanti-RUNX3 ASOanti-RUNX-3 ASOanti-RUNX 3 ASO
02
Targets
RUNX3 (Runt-related transcription factor 3)
Beyond the preview
Go deeper on anti-RUNX3 antisense oligonucleotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-RUNX3 antisense oligonucleotide.